Kornimate/medical-research-clean huggingface dataset:
medico-economic comparison between treatment with panretinal photocoagulation by laser in 1 session versus 4 sessions in diabetic retinopathy

Conditions: Diabetic Retinopathy

Summary: despite the fact that the efficacy of a single session of multispot laser has been demonstrated in the treatment of patients with diabetic retinopathy as compared with four sessions of single-spot laser, the management of panretinal photocoagulation in the different healthcare establishments in france has remained unchanged notably because there is no specific reimbursement for this new treatment protocol. although the benefits of reducing the number of sessions and thus the costs associated with the treatment for the patient and the payer seem to be obvious, the medico-economic impact of modifying the treatment strategy thanks to the technological changes must be evaluated to provide deciders with additional information.


Eligibility criteria:
inclusion criteria: * persons who have provided written informed consent * patients with type 1 or 2 diabetes according to world health organisation diagnostic criteria. * patients with severe non proliferative or early proliferative diabetic retinopathy * visual acuity of the treated eye \>= 20/32 snellen (≥ 0.63 monoyer units or ≥ 70 letters early treatment diabetic retinopathy study) * visual acuity of the contralateral eye \>= 20/200 snellen (≥ 0.10 monoyer units or ≥ 35 letters early treatment diabetic retinopathy study) * patients with a central macular thickness of 350 μm or less on spectral domain - optical coherence tomography * patients with national health insurance cover * patients over 18 years old exclusion criteria: * uncontrolled diabetes in the previous 6 months with intensive insulin therapy (glycated haemoglobin \> 11). * uncontrolled hypertension. * florid diabetic retinopathy floride. * macular oedema due to causes other than diabetic retinopathy or in a context of vitreomacular traction. * history of intravitreal treatment with anti-angiogenic agent or corticosteroids within the 12 previous months. * history of treatment with laser in panretinal photocoagulation or focal laser on the treated eye. * history of eye surgery or laser capsulotomy within the previous 6 months * history of renal failure requiring dialysis or kidney transplantation for diabetic nephropathy. * contra-indication for tropicamide or neo-synephrine * history of uncontrolled glaucoma or hypertonia * patient with aphakia * adult under guardianship * pegnant or breast-feeding women
short term effectiveness study of juxta-fit versus trico bandages in the treatment of leg lymphedema

Conditions: Lymphedema

Summary: juxta-fit is used for compression treatment. juxta-fit is an inelastic compression device which can be easily adjusted to the circumference of the limb and is usually used during the maintenance phase of lymphedema treatment. the aim of the study is to assess the effectiveness of juxta-fit in the initial treatment phase of leg lymphedema compared to the traditional treatment with trico bandages in relation to interface pressure and to explore if self-management by juxta fit is efficient after a short demonstration. data are collected at 0-2-24 hours

application of marketed compression systems (juxta-fit or trico bandages) used for treatment by trained specialists with assessment of the interface pressure and volume reduction. for the first two hours, bandages and juxta fit will be applied by experienced medical staff and the use of the juxta-fit device will be explained to the patient. thereafter the devices will be removed and patients in the juxta fit group will apply the device themselves in the treatment. in this second phase after 2 hours, patients may adjust the juxta-fit according to their needs and comfort when they feel the device is getting too loose as activity of self-management during 24 hours. the patient will document this in a diary. detailed measuring data: volumetry: measurements after 0h, 2h and 24 h by using classic water displacement apparatus. pressure: measurements after 0h, 2h (pre and post system change) and 24 h at the b1 region: * supine and standing to calculate the static stiffness index (ssi); * supine with and without dorsal flexion to calculate the dynamic stiffness index (dsi). circumference measurement as safety parameter at 5 cm above the upper part of the patella the circumference is measured at 0-2-24 hours to monitor eventual fluids shift. questionnaire - the visual analog scale (vas) is used at 0 (pre-treatment), 2 and 24 hours to register the comfort of the materials used.

Eligibility criteria:
inclusion criteria: * gender: male or female * more than 18 years of age * patients with distal lymphedema of the leg requiring multilayer lymphedema bandaging of the leg stage 2/3 (pitting component) * the patient is able to understand the study and is willing to give written informed consent to the study. exclusion criteria: * allergy to one of the used materials * proximal lymphedema (involvement of thigh, genitalia) * severe systemic diseases causing peripheral edema * acute superficial or deep vein thrombosis * arterial occlusive disease (stadium ii, iii or iv) ankle brachial pulse index (abpi) \<0,8 * local infection in the therapy area * auto-immunological disorders or vasculitis * use of systemic corticosteroids * inability to don, doff, and adjust the juxta-fit * if the ankle circumference around the malleoli is greater than 38cm or if the difference between the arch circumference and the circumference around the base of the toes is greater than 7cm.

Keywords: lymphedema conservative treatment compression therapy interface pressure
an efficacy and safety study of shrna-modified cd34+ cells in hiv-infected patients.

Conditions: HIV Infections; AIDS

Summary: the purpose of the study is to evaluate the efficacy and safety of autologous cd34+ cells that stably express multiplexed shrna to treat hiv infection.

cd34+ cells will be isolated from mobilized pbmc of hiv patients. the cells will be lentivirally transduced with multiplexed shrnas in the same vector that target ccr5 and hiv genome. such modified cells will be infused back to the patients who have received bulsufan preconditioning before infusion. the patients will then be evaluated for efficacy and safety.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) from 18 - 25; body weight ≥50kg. * diagnosis of hiv infections/aids based on "diagnostic criteria for hiv/aids" ws 293-2008. * no antiretroviral therapy (art) in the past 6 weeks and refuse to receive art. * cd4 t cell count ≥350/μl. * no plan for pregnancy in the near future and agree to practice non-drug based contraception. * voluntary to participate in the study, comply with the study design to complete all monitory measurements, and agree to sign the study agreement. exclusion criteria: * existence of infections/opportunistic tumors. * mutations in the shrna target sequences. * white blood cell count \<3x10\^9/l, neutrophil count \<1.5x10\^9/l, hemoglobin \<110g/l, platelet count \<100x10\^9/l. * liver diseases (hbv, chronic hcv infection, congenital liver metabolic disease), abnormal liver functions (test value 2x above normal). * kidney deficiency (creatinine level above the upper limit of normal levels). * severe chronic disease, metabolic disease (e.g., diabetes), neurological and psychiatric diseases. * history of pancreatitis. * women in pregnancy, lactating or at reproductive age who do not practice contraception. * allergy to agents or drugs used in the study. * verified or suspected abuse of alcohol and drugs. * participated in other clinical trials within 3 months. * based on investigator's assessment, those who are unfit for the study (e.g., general weakness, poor compliance with study design). * personal or family history of tumors.

Keywords: hiv aids lentivirus shrna multiplex gene therapy
"l-sandwich" strategy in the true coronary bifurcation lesions

Conditions: Coronary Disease

Summary: the treatment of coronary bifurcation lesions continue to remain challenges. due to the complexity of the anatomical structure and the limitations of imaging, there are poor attachment and under-expansion of the stent at the branch ostium, which causes in-stent thrombosis and restenosis. the delayed re-endothelialization arise from multi-layer stents. the one-stent strategy causes the displacement of the plaques and ridges of the branch ostium, and thus insufficient blood flow to the branches. the "l-sandwich" strategy, stents were implanted in the main vessel(mv) and the shaft of side branch(sb) respectively, then a drug-coated balloon(dcb) was applied to the ostium of the sb, to improve the tedious operation process in true bifurcation lesions and reduce postoperative complications. the purpose of this study was to explore the feasibility, safety, and efficacy of the "sandwich" strategy.

this is a study to evaluate the application of l-sandwich in true bifurcation coronary artery disease.all eligible patients were randomly divided into three groups: experimental group 1: dual stent group: both main vessel(mv) and side branch(sb) were stented, and dk-crush or culotte were performed according to different pathological characteristics. experimental group 2: single stent + drug-coated balloon（dcb）: stent was implanted in the mv, and only drug balloon was used in the sb.experimental group 3: l-sandwich : stent was implanted in the mv, and the branch was implanted 3-5mm away from the ostium，and the dcb was implanted in the ostium of the branch.ivus+ angiography was used to guide the operation and evaluate the outcome.

Eligibility criteria:
inclusion criteria: * patients with true bifurcation disease with sb lesion length\>25mm exclusion criteria: * sb diameter\<2.5mm * presence of cardiogenic shock or cardiopulmonary resuscitation * expected survival \<1 year * allergy to indexed medications * intolerable to dual antiplatelet therapy * pregnant * severe calcification needing rotational atherectomy
screening for cervical intraepithelial neoplasia using self-collected menstrual blood

Conditions: HPV - Anogenital Human Papilloma Virus Infection

Summary: the purpose of this study is to investigate the feasibility and efficacy of assessing hr-hpv dna and hpv e6/e7 mrna via self-collected menstrual blood in a smart menstrual pad. in other words, can the investigators detect the high risk strains of the human papilloma virus (hpv) that are associated with cervical cancer in self-collected menstrual blood, as an alternative to collecting vaginal swabs.


Eligibility criteria:
inclusion criteria: there will be two study groups: 1) menstruating women over the age of 18 who have previous history of hr-hpv in the last 18 months and 2) menstruating women over the age of 18 who do not have a previous history of hr-hpv. exclusion criteria: * women younger than 18 years old or are not menstruating regularly

Keywords: menstrual blood, high risk hpv
efficacy of tranexamic acid in reducing blood loss during cesarean section because of placenta previa

Conditions: Postpartum Haemorrage Sever Bleeding After Delivery

Summary: this study evaluate role of tranexamic acid in reducing blood loss among pregnant women undergoing cesarean section because of placenta previa .half of participants will receive tranexamia acid drug while the other half will receive placebo.

tranexamic acid used in the field of obstetrics to decrease blood loss during and after cesarean section . tranexamic acid is an antifibrinolytic agent which cause reversible and competitive blockade of the lysine binding sites in plasminogen molecules . it is a synthetic analog of amino acid lysine and its action is to reduce blood loss

Eligibility criteria:
inclusion criteria: * age 18 -38 body mass index \<30 , diagnosis of placenta previa exclusion criteria: * patient with bleeding disorder , hepatic and renal disease. contraindication to tranexamic acid as allergy , hypersensitivity to tranexamic acid and known thromboembolic event during pregnancy . other causes ofantepartum haemorrhage eg :accidental haemorrhage, rupture uterus. type 1,2 of placenta previa anterior type 3,4 of placenta previa posterior causes of overdistended uterus like :multiple pregnancy, polyhydraminos

Keywords: obstetric bleeding placenta previa
monitorings the physiological mechanism of airway pressure release ventilation in ards patients by eit

Conditions: Electrical Impedance Tomography; ARDS

Summary: effects of airway pressure release ventilation on pulmonary ventilation, shunt and perfusion in patients with ards

effects of airway pressure release ventilation on respiratory mechanisms including ventilation distribution, intrapulmonary shunt and v/q match in lungs of ards evaluated by eit at different time points.

Eligibility criteria:
inclusion criteria: 1. 18 years old \< age \< 80 years old 2. diagnosed as moderate or severe ards according to the berlin 2014 definition 3. predicted aprv mechanical ventilation for more than 72 hours exclusion criteria: excluded if any of the following exclusion criteria are met: 1. aprv contraindications such as pneumothorax, severe chronic obstructive pulmonary disease, severe asthma, intracranial hypertension 2. pregnant women 3. severe cardiac dysfunction (new york heart association class iii or iv, acute coronary syndrome or sustained ventricular tachyarrhythmia), right heart enlargement due to chronic cardiopulmonary disease, cardiogenic shock or cardiac hand 4. refractory shock 5. bmi\>35
hip and knee moments normal and with scoliosis

Conditions: Scoliosis Idiopathic

Summary: kinetic analysis appears to be useful in providing objective information regarding the gait abilities of scoliotic patients which is difficult to be observed in a clinical setting. objective: the aim of the study was to analyze the hip and knee peak abductor moments during gait in subjects with idiopathic scoliosis.

the hip and knee abductors' moments normalized to body weight have been investigated in normal subjects and subjects with idiopathic scoliosis. the scoliosis group included a twenty-two-moderate idiopathic dorso-lumbar single scoliotic curve. the control group contained a normal twenty-two subjects. 3d motion analysis system and force plat were used for data collection for hip and knee abductor moment. manova was used to study the difference between normal and scoliotic groups' hip and knee abductor moments in both lower limbs. at alpha level of significance of 0.05.

Eligibility criteria:
inclusion criteria: * normal subjects free from any musculoskeletal problems * subjects with moderate idiopathic scoliosis (cobb angle 25-35) exclusion criteria: * any musculoskeletal affection rather than scoliosis, neurological manifestations, or previous major surgeries

Keywords: idiopathic scoliosis-gait-moment
comparison of aerobic exercise and spinal stabilization exercises in women with primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: the aim of the study is to compare the effects of aerobic exercise and spinal stabilization exercises in women with primary dysmenorrhea (pd) complaints.

pd is the cramping pain that comes before or during a period. different exercise approaches have positive effects in pd. comparing the effects of these exercise approaches is needed to determine the effects on pd.

Eligibility criteria:
inclusion criteria: women with primary dysmenorrhea complaint according to the primary dysmenorrhea consensus guide, over 18 years of age, having a mean pain intensity of moderate and higher according to the visual analogue scale in the last 6 months, having a regular menstrual cycle (28±7 days), volunteered to participate in the study. exclusion criteria: having a pathological history and radiological findings pointing to secondary dysmenorrhea, using oral contraceptives/antidepressants at least 6 months, receiving hormone therapy, undergoing pelvic surgery, pregnant, giving birth, using an intrauterine device, having neurological, orthopedic and/or rheumatological diseases having a history of ischemic heart disease (recently myocardial infarction, angina pectoralis, uncontrolled hypertension, etc.), having a psychiatric disease, having a history of malignancy
biomarker for alport syndrome (bioalport)

Conditions: Nephritis, Hereditary; Hematuria-Nephropathy-Deafness Syndrome

Summary: international, multicenter, observational, longitudinal monitoring study to identify biomarker/s for alport syndrome and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

alport syndrome (as) is a progressive hereditary glomerular disease with the prevalence 1 in 50,000. as is caused by pathogenic variants in the col4a3, col4a4, and col4a5 genes encoding type iv collagen α3, α4, and α5 chains, respectively. there are three modes of inheritance: x-linked alport syndrome (xlas), autosomal recessive as (aras), and autosomal dominant as (adas). alport syndrome causes progressive kidney damage. the glomeruli and other normal kidney structures such as tubules are gradually replaced by scar tissue, leading to kidney failure. boys with alport syndrome, regardless of the genetic type, eventually develop kidney failure. these boys often need dialysis or transplantation during their teenage or young adult years, but kidney failure can occur as late as 40-50 years of age in some men with alport syndrome. most girls with the x-linked type of alport syndrome do not develop kidney failure. however, as women with alport syndrome get older the risk of kidney failure increases. currently, diagnosis of alport syndrome relies on careful evaluation of the patient's signs and symptoms, along with the family history. hearing and vision should also be tested. the evaluation can also include a blood test, urine tests, and a kidney biopsy to determine alport syndrome. a genetic test is crucial to confirm the diagnosis and determine the genetic type of alport syndrome. there is no cure for alport syndrome; however, symptomatic treatment can help relieve symptoms. kidney transplantation is usually very successful in people with alport syndrome and is considered the best treatment when end-stage kidney failure is approaching. the aim of this study to identify biomarker/s for alport syndrome and to explore their clinical robustness, specificity, and long-term variability, in the attempt to offer access to earlier diagnosis and treatment monitoring.

Eligibility criteria:
inclusion criteria * informed consent is obtained from the participant or the parent/ legal guardian. * the participant is aged between 2 months and 50 years * the diagnosis of alport syndrome is genetically confirmed by centogene exclusion criteria * informed consent is not obtained from the participant or from the parent/ legal guardian * the participant is younger than 2 months or older than 50 years * the diagnosis of alport syndrome is not genetically confirmed by centogene

Keywords: alport syndrome biomarker
outcome of patients with primary aldosteronism

Conditions: Primary Aldosteronism; Primary Aldosteronism Due to Aldosterone Producing Adenoma; Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral); Adrenalectomy; Status; Mineralocorticoid Excess; Mineralocorticoid Antagonists [Aldosterone Antagonists] Causing Adverse Effects in Therapeutic Use; Cardiovascular Morbidity; Chronic Renal Disease; Hypokalemia

Summary: majority of patients with hypertension have primary hypertension (without an underlying cause). primary aldosteronism (pa) is the most common cause of secondary hypertension, and can be found in 5-10% of patients locally. pa is caused by excessive release of a hormone (aldosterone) from the adrenal glands, which can be unilateral (one gland) or bilateral (both glands). it has been shown that excess aldosterone has other harmful effects in addition to hypertension, such as directly affecting the heart, blood vessels, kidneys, leading to increased cardiovascular morbidity and mortality. this is supported by studies showing reversal of these effects after treatment for pa. the investigators aim to assess the long-term cardiovascular, and renal outcomes of patients with pa, compared to patients with essential hypertension.


Eligibility criteria:
inclusion criteria: * patients with suspected primary aldosteronism exclusion criteria: * nil
returning genome and metabolome data to finterveys 2017 participants: p5.fi finterveys study

Conditions: Coronary Heart Disease; Type 2 Diabetes; Deep Vein Thrombosis

Summary: p5.fi study - p4 together with a fifth 'p' and '.fi' for population health finally implemented in finland - studies the value of returning genetic and metabolomic risk information in two diseases (coronary heart disease and type 2 diabetes) and one feature (venous thromboembolism). the hypothesis of the study is that 1) combining genetic and metabolic risk with traditional risk factors adds value to the personal risk assessment of these diseases, 2) such risk information can be provided to individuals using a web based user portal in an easily understandable and useful format, and 3) receiving genetic and metabolomic risk information has an effect on the health of the study participants. the study is a continuation of finhealth 2017 -study, which involved more than 7,000 finns from around the country. the participants of finhealth were invited to participate in p5.fi -study. the new research utilises information, samples, and measurements obtained in the finhealth study. prospective clinical significance of selected genetic and metabolomic risk scores will be studied in 30.000 finnish individuals. the study will analyze the genetic and metabolomic profile of the p5.fi participants and develop and test a protocol for returning them health related risk information. the impact of the intervention will by followed up by questionnaires and national health registers for five years.


Eligibility criteria:
inclusion criteria: - only participants of finhealth 2017 -study are eligible for the study exclusion criteria: - participants not part of finhealth 2017 -study are not eligible

Keywords: genetic risk score metabolic risk score health promotion web-based intervention
lp(a) with ccta assessed parameters and clinical outcomes

Conditions: Coronary Artery Disease

Summary: lipoprotein(a) \[lp(a)\] is a risk factor for cardiovascular events, although the underlying mechanism remains unclear. this study evaluated the relationship between lp(a) and high-risk attributes (hra) by coronary computed tomography angiography (ccta) as well as their prognostic value.


Eligibility criteria:
inclusion criteria: * patients with lp(a) meaured within 1 week of ccta examination. exclusion criteria: * unstable angina pectoris * acute myocardial infarction * new york heart association class iii-iv heart failure * with a history of bypass surgery * active infection * respiratory failure * chronic kidney disease (estimated glomerular filtration rate \[egfr\] \<60 ml/min/1.73 m2) * liver dysfunction (liver enzyme \>3 upper reference limit \[url\] or bilirubin \>2 url) * malignancy * systemic connective tissue disease * poor ccta imaging quality not suitable for analysis * other situations not suitable for the study